Literature DB >> 11583578

Calmodulin inhibitors trigger the proteolytic processing of membrane type-1 matrix metalloproteinase, but not its shedding in glioblastoma cells.

B Annabi1, A Pilorget, N Bousquet-Gagnon, D Gingras, R Béliveau.   

Abstract

Most transmembrane proteins are subjected to limited proteolysis by cellular proteases, and stimulation of cleavage of membrane proteins by calmodulin (CaM) inhibitors was recently shown. The present study investigated the ability of several CaM inhibitors to induce the proteolytic cleavage of the membrane type-1 matrix metalloproteinase (MT1-MMP) from the cell surface of highly invasive U-87 glioblastoma cells. Although no shedding of a soluble MT1-MMP form was induced by CaM inhibitors in the conditioned media, we showed that these inhibitors induced MT1-MMP proteolytic processing to the 43 kDa membrane-bound inactive form that was not correlated with an increase in proMMP-2 activation but rather with an increase in tissue inhibitor of MMPs (TIMP)-2 expression levels. Moreover, this proteolytic processing was sensitive to marimastat suggesting the involvement of MMPs. Interestingly, CaM inhibitors antagonized concanavalin A- and cytochalasin D-induced proMMP-2 activation, and affected the cytoskeletal actin organization resulting in the loss of migratory potential of U-87 glioblastoma cells. Cytoplasmic tail-truncated MT1-MMP constructs expressed in COS-7 cells were also affected by CaM inhibitors suggesting that these inhibitors stimulated MT1-MMP proteolytic processing by mechanisms independent of the CaM-substrate interaction. We also propose that TIMP-2 acts as a negative regulator of MT1-MMP-dependent activities promoted by the action of CaM inhibitors in U-87 glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583578      PMCID: PMC1222150          DOI: 10.1042/0264-6021:3590325

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  45 in total

1.  Induction of matrix metalloproteinase-9 requires a polymerized actin cytoskeleton in human malignant glioma cells.

Authors:  S K Chintala; R Sawaya; B B Aggarwal; S Majumder; D K Giri; A P Kyritsis; Z L Gokaslan; J S Rao
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 2.  Matrix metalloproteinases and metastasis.

Authors:  D E Kleiner; W G Stetler-Stevenson
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

3.  Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines.

Authors:  P Kurschat; P Zigrino; R Nischt; K Breitkopf; P Steurer; C E Klein; T Krieg; C Mauch
Journal:  J Biol Chem       Date:  1999-07-23       Impact factor: 5.157

Review 4.  Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization.

Authors:  W T Chen; J Y Wang
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

5.  Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism.

Authors:  J Kahn; B Walcheck; G I Migaki; M A Jutila; T K Kishimoto
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

6.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.

Authors:  K Lehti; J Lohi; H Valtanen; J Keski-Oja
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells.

Authors:  K Shofuda; K Moriyama; A Nishihashi; S Higashi; H Mizushima; H Yasumitsu; K Miki; H Sato; M Seiki; K Miyazaki
Journal:  J Biochem       Date:  1998-08       Impact factor: 3.387

8.  Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase.

Authors:  I Kazes; F Delarue; J Hagège; L Bouzhir-Sima; E Rondeau; J D Sraer; G Nguyen
Journal:  Kidney Int       Date:  1998-12       Impact factor: 10.612

9.  Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts.

Authors:  H Li; D E Bauzon; X Xu; H Tschesche; J Cao; Q A Sang
Journal:  Mol Carcinog       Date:  1998-06       Impact factor: 4.784

10.  MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

Authors:  K Holmbeck; P Bianco; J Caterina; S Yamada; M Kromer; S A Kuznetsov; M Mankani; P G Robey; A R Poole; I Pidoux; J M Ward; H Birkedal-Hansen
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

View more
  2 in total

1.  A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.

Authors:  Borhane Annabi; Mounia Bouzeghrane; Jean-Christophe Currie; Robert Hawkins; Hélène Dulude; Luc Daigneault; Marcia Ruiz; Jan Wisniewski; Seema Garde; Shafaat A Rabbani; Chandra Panchal; Jinzi J Wu; Richard Béliveau
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP.

Authors:  Jin-Ah Cho; Pamela Osenkowski; Huiren Zhao; Seaho Kim; Marta Toth; Kristina Cole; Amro Aboukameel; Allen Saliganan; Lucia Schuger; R Daniel Bonfil; Rafael Fridman
Journal:  J Biol Chem       Date:  2008-04-15       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.